logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10640498 B1

PDFFull Text
Date of Patent:
May. 05, 2020

Filed:

Feb. 16, 2017

Compounds

Applicant:

Mission Therapeutics Limited, Cambridge, GB;

Inventors:

Karl Richard Gibson, Sandwich, GB;

Alison Jones, Cambridge, GB;

Mark Ian Kemp, Cambridge, GB;

Andrew Madin, Cambridge, GB;

Martin Lee Stockley, Cambridge, GB;

Gavin Alistair Whitlock, Sandwich, GB;

Michael D. Woodrow, Cambridge, GB;

Assignee:

MISSION THERAPEUTICS LIMITED, Cambridge, GB;

Attorney:
Primary Examiner:

Alicia L Otton

Int. Cl.
CPC ...
C07D 417/12 (2006.01); C07D 401/14 (2006.01); C07D 401/06 (2006.01); C07D 401/12 (2006.01); C07D 403/06 (2006.01); C07D 403/14 (2006.01); C07D 413/12 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 487/10 (2006.01); C07D 403/12 (2006.01); C07D 413/04 (2006.01); C07D 413/06 (2006.01);
U.S. Cl.
CPC ...
C07D 417/12 (2013.01); C07D 401/06 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/06 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 413/04 (2013.01); C07D 413/06 (2013.01); C07D 413/12 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07D 487/10 (2013.01);
Abstract

The present invention relates to novel compounds of formula (I) and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and in the treatment of cancer.

Find Patent Forward Citations

Loading…